COMMUNITY - the COVID-19 Immunity Study Tracking Immune Responses After Infection and Vaccination In Healthcare Workers and Hospitalized Patients

What this Trial Is About

Researchers are evaluating immune responses to SARS-CoV-2 infection and vaccination in healthcare workers and hospitalized COVID-19 patients. The study, named COMMUNITY, aims to enroll 5,000 healthcare workers and 500 COVID-19 patients at Danderyd Hospital in Stockholm, Sweden. It also investigates immune responses to Influenza A/B and Respiratory Syncytial Virus (RSV) infections and vaccinations, with the goal of understanding antibody and cellular immune responses over time. Participants undergo blood and mucosal sampling (including saliva and nasal secretions) every four months, with additional sampling and PCR testing during sub studies. PCR tests detect infections from SARS-CoV-2, Influenza A/B, and RSV A/B. Data on infection and vaccination history is collected from national registries, while clinical and demographic information is gathered through a smartphone app. All samples are stored in Biobank Sweden for further analysis. During the study, participants provide blood and mucosal samples at regular four-month intervals and complete questionnaires via a mobile app. Researchers monitor antibody and cellular immune responses, viral infections, and mucosal microbiome changes. The study follows participants from 2022 to 2026, tracking immune responses longitudinally to better understand protection against these respiratory viruses.

COMMUNITY - the COVID-19 Immunity Study